Australian scientists have pioneered the development of a drug-loaded 3D printed film, which is crafted from a gel containing specific doses of the anti-cancer drugs 5-fluorouracil and cisplatin. This innovation can effectively eradicate cancer cells, significantly reduce recurrence rates, and minimize the toxicity associated with traditional chemotherapy. The research findings were published in the latest issue of the "International Journal of Pharmaceutics."
Globally, over 800,000 people are diagnosed with liver cancer annually. The primary treatment approach involves surgical removal of tumors followed by chemotherapy. While crucial for preventing recurrence, chemotherapy often brings side effects, leading many patients to discontinue treatment.
In response, researchers have developed a novel postoperative chemotherapy-loaded film capable of directly releasing 5-fluorouracil and cisplatin to the surgical site. Results indicate its efficacy in eliminating residual cancer cells and mitigating the side effects of conventional chemotherapy. Initially developed as an adjunct therapy for liver cancer, this film can also be employed in treating ovarian cancer, head and neck cancer, and other malignancies.
Moreover, the film can control drug release for up to 23 days, ensuring sustained therapeutic effects.
Utilizing cutting-edge 3D printing technology, researchers can tailor treatment plans for each patient, customizing the film's geometry, adjusting drug release profiles, and modifying active ingredients. Additionally, the film exhibits biodegradable properties.
The research team plans to conduct preclinical trials to further elucidate the correlation between tumor size and optimal drug delivery and dosage, laying the groundwork for future clinical trials.
